NVIDIA To $230? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts adjusted targets for HD, DUOT, CNSY, ECL, DLB, NVDA and KLAR, while maintaining their existing ratings.

Last updated: 2026-11-19 02:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cerenome, Inc. (CNSY) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0.69, with a market capitalization of $6.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.43 to $4.25. This page covers its latest market performance, valuation, price trends and company information.
$6.99M | |
$0.64 | |
$0.78 | |
$0.63 | |
$0.63 | |
512.33K | |
803.31K | |
-- | |
$4.25 | |
$0.43 | |
-- | |
2026-09-30 |
Cerenome, Inc. (CNSY) last closed at $0.69 as of 2026-11-19 01:00:00, up 7.52% ($0.05) from the previous close of $0.63.
During the latest regular trading session, CNSY traded between $0.63 and $0.78, with a volume of 512.33K shares. The closing price was near the middle and near the lower end of its 52-week range.
CNSY is down 12.06% as of the last close.
Over the past seven days, Cerenome, Inc. (CNSY) moved from $0.57 to $0.69, representing a gain of 21.10% ($0.12).
The stock traded between $0.43 and $1.18 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.67 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.8%
CNSY is currently trading at $0.69, placing it 6.8% of the way from its 52-week low of $0.43 to its 52-week high of $4.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Cerenome, Inc. and CNSY stock.
Wall Street analysts adjusted targets for HD, DUOT, CNSY, ECL, DLB, NVDA and KLAR, while maintaining their existing ratings.
HC Wainwright & Co. analyst Sean Lee maintains Cerenome (NASDAQ:CNSY) with a Buy and raises the price target from $1 to $7.
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial
Eligible investors can buy real shares of Cerenome, Inc. (CNSY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CNSY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CNSY shares and USD.
CNSY Shares to USD
1.00 CNSY shares = 0.69 USD
Calculations are estimates based on the latest available price and are for reference only.